Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical trial results show promise of targeting autophagy BRAF mutant melanoma.

Autophagy - 1 Jun 2022

Amaravadi Ravi K

Abstract excerpt

Macroautophagy/autophagy is a resistance mechanism to targeted therapy in BRAF mutant cancers. Preclinical evidence and clinical trial data demonstrate that hydroxychloroquine (HCQ) is an effective autophagy inhibitor at clinically achievable concentrations. Here we highlight the results of a recently published single-arm phase I/II multi-institution trial of dabrafenib, trametinib, and the autophagy inhibitor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Skin Neoplasms
Share to Antineoplastic Combined Chemotherapy Protocols
Share to Autophagy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydroxychloroquine

Share to Melanoma

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Pyrimidinones

Source

Open in PubMed Open full text

Identifiers

PMID: 35156519
DOI: 10.1080/15548627.2022.2038899
PMCID: PMC9225520

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical trial results show promise of targeting autophagy BRAF mutant melanoma.PMID 35156519Read ↗

BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma.Semantic proximity Read ↗

The Cytoprotective Role of Autophagy in Response to BRAF-Targeted Therapies.Semantic proximity Read ↗

A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors.Semantic proximity Read ↗

Targeting Autophagy in Cancer: Recent Advances and Future Directions.Semantic proximity Read ↗

Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib.Semantic proximity Read ↗

ALDH1A1 and HLTF modulate the activity of lysosomal autophagy inhibitors in cancer cellsSemantic proximity Read ↗

Trametinib and Hydroxychloroquine (HCQ) Combination Treatment in KRAS-Mutated Advanced Pancreatic Adenocarcinoma: Detailed Description of Two Cases.Semantic proximity Read ↗

Hydroxychloroquine Synergizes With The PI3K Inhibitor BKM120 to Exhibit Antitumor Efficacy Independent of AutophagySemantic proximity Read ↗

FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMASemantic proximity Read ↗

Androgen receptor-dependent DRAM1 activation drives autophagic resistance to BRAF inhibitors in BRAFV600-mutant melanoma.Semantic proximity Read ↗

A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Hydroxychloroquine (HCQ) reverses anti-PD-1 immune murine checkpoint blockade: TCF1 as a marker in humans for COVID-19 and HCQ therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.